Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 6/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.31 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 3/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899870 | 0.79 | GABRG2 (0.35) | PTGS2PTGS1F2RL1GABRG2GABRB3 | |
| SCHEMBL899670 | 0.78 | NR3C2 (0.36) | NR3C2MDM2GPR139 | |
| SCHEMBL899633 | 0.76 | NR3C2 (0.35) | NR3C2MDM2GPR139 | |
| SCHEMBL899164 | 0.74 | PTGES (0.32) | NR3C2PTGS2PTGS1 | |
| SCHEMBL898920 | 0.74 | NR3C2 (0.37) | NR3C2MDM2NR3C1GPR139HSD11B1 | |
| SCHEMBL899285 | 0.74 | NR3C2 (0.35) | NR3C2MDM2GPR139 | |
| SCHEMBL898723 | 0.72 | NR3C2 (0.36) | NR3C2MDM2GPR139 | |
| SCHEMBL898935 | 0.72 | NR3C2 (0.36) | NR3C2MDM2GPR139HSD11B1 | |
| SCHEMBL898925 | 0.72 | NR3C2 (0.34) | NR3C2MDM2 | |
| SCHEMBL898213 | 0.71 | NR3C2 (0.35) | NR3C2MDM2GPR139HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621907-A1 | FUNGICIDAL IMIDAZOLES | E.I. Du Pont De Nemours And Company (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | EI DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012044650-A1 | FUNGICIDAL IMIDAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | CYP1A1, CYP1B1, CYP2E1 | NR3C2 2193/4885PTGS2 1076/4885MDM2 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.